{"analyses":[{"ciLowerLimit":"2.178","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.662","estimateComment":"Response rate ratio: albumin-bound paclitaxel + gemcitabine /gemcitabine alone","groupDescription":"PA+G/PG = response rate ratio of albumin bound paclitaxel + gemcitabine / gemcitabine.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Response Rate Ratio","paramValue":"3.19","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.1","upperLimit":"27.2","value":"23"},{"groupId":"OG001","lowerLimit":"5.0","upperLimit":"10.1","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"431"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"Objective tumor response was summarized as the percentage of participants who achieved a confirmed complete (CR) or partial response (PR) based on an independent blinded radiology assessment of response using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Using RECIST Version 1.0, participants were to achieve either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Albumin-bound paclitaxel (ABI-007)/Gemcitabine: ABI-007 125 mg/m\\^2 administered intravenously (IV) in combination with Gemcitabine 1000 mg/m\\^2 IV weekly for 3 weeks on Days 1, 8, and 15 followed by one week of rest","id":"OG000","title":"Albumin-bound Paclitaxel (ABI-007)/Gemcitabine"},{"description":"Gemcitabine 1000 mg/m\\^2 administered IV weekly for 7 weeks through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks on Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward)","id":"OG001","title":"Gemcitabine"}],"paramType":"NUMBER","populationDescription":"Intent to Treat population (ITT population) consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Assessment every 4 weeks after initial response; Day 1 to data cut off of 17 Sept 2013; maximum time on study 37 months","title":"Percentage of Participants Who Achieved an Objective Confirmed Overall Response by Independent Radiological Review (IRR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}